PKI PerkinElmer Q1 2026 Earnings: $0.36 EPS, $711M Revenue

PerkinElmer, Inc. (PKI) reported first-quarter 2026 earnings on May 5, delivering $0.36 earnings per share and $711.12 million in revenue. The healthcare diagnostics and life sciences company faced a mixed market reception, with shares declining 0.91% following the announcement. Trading at $115.24, the stock sits well below its $170 year-high, reflecting broader sector pressures. With a market cap of $14.46 billion, PerkinElmer continues serving pharmaceutical, biotech, and research institutions worldwide. Meyka AI rates PKI with a grade of B, suggesting a hold position for investors monitoring the company’s recovery trajectory.

Q1 2026 Earnings Results and Market Reaction

PerkinElmer’s first-quarter performance showed modest profitability amid challenging market conditions. The company delivered $0.36 per share in earnings and generated $711.12 million in quarterly revenue.

Stock Price Movement

Following the earnings release, PKI shares fell 0.91% to close at $115.24. The stock traded within a narrow range, hitting a day low of $114.67 and day high of $117.21. This modest decline suggests cautious investor sentiment despite the earnings report. The stock remains significantly below its 52-week high of $170, indicating sustained pressure on the healthcare diagnostics sector.

Valuation Metrics

The company trades at a P/E ratio of 41.45, reflecting elevated valuation relative to historical norms. With 125.44 million shares outstanding, PerkinElmer maintains a solid equity base. The price-to-sales ratio of 4.98 indicates investors are paying a premium for each dollar of revenue generated by the company.

Financial Performance and Operational Efficiency

PerkinElmer’s operational metrics reveal mixed signals about business health and profitability trends. The company’s financial structure shows both strengths and areas requiring attention.

Revenue and Profitability Trends

With $711.12 million in quarterly revenue, PerkinElmer maintains steady sales generation across its two core segments: Discovery & Analytical Solutions and Diagnostics. The company’s net profit margin of 8.26% demonstrates reasonable profitability despite competitive pressures. Operating income grew 15.36% year-over-year, suggesting improved operational efficiency and cost management initiatives.

Cash Flow and Liquidity

Operating cash flow per share reached $5.24, while free cash flow per share stood at $4.55. The company maintains a current ratio of 1.72, indicating solid short-term liquidity. Free cash flow growth surged 53.69% year-over-year, a significant positive indicator for capital allocation and shareholder returns.

Segment Performance and Business Drivers

PerkinElmer operates through two distinct business segments serving different market verticals. Each segment faces unique growth dynamics and competitive pressures.

Discovery & Analytical Solutions Segment

This segment provides reagents, informatics, detection technologies, and analytical instruments for life sciences research and industrial applications. The division serves pharmaceutical companies, biotech firms, academic institutions, and environmental testing markets. Analytical technologies for environmental, food, and industrial markets remain core revenue drivers for this business unit.

Diagnostics Segment

The Diagnostics division focuses on early detection of genetic disorders and infectious disease testing. Products include instruments, reagents, assay platforms, and software for pregnancy screening, childhood disorder detection, and genomic workflows. This segment supports oncology, immunodiagnostics, and drug discovery applications, serving public health authorities and private healthcare organizations globally.

Meyka AI Grade and Investment Outlook

Meyka AI rates PKI with a grade of B, reflecting balanced fundamentals with room for improvement. The rating suggests a hold position for current investors while new buyers should await better entry points.

Grade Composition and Analysis

The B grade incorporates multiple factors: sector comparison (16%), industry benchmarking (16%), financial growth metrics (12%), key financial ratios (16%), and analyst consensus (14%). PerkinElmer scores 61.79 out of 100, placing it in the middle tier of healthcare diagnostics companies. The grade reflects solid operational performance offset by valuation concerns and sector headwinds.

Forward Considerations

Investors should monitor PerkinElmer’s ability to grow earnings while managing debt levels. The company’s debt-to-equity ratio of 0.47 remains manageable. Return on equity of 3.26% suggests capital efficiency challenges requiring management attention and strategic improvements in capital deployment.

Final Thoughts

PerkinElmer’s Q1 2026 earnings of $0.36 per share and $711.12 million revenue reflect steady operational performance in a challenging healthcare environment. The 0.91% stock decline post-earnings indicates measured investor caution despite solid cash flow generation and improved operating margins. With a B grade from Meyka AI, the company presents a hold case for existing shareholders while potential buyers should await improved valuation or stronger earnings acceleration. PerkinElmer’s diversified exposure to life sciences research and diagnostics provides long-term growth potential, though near-term headwinds persist. Management’s focus on operational efficiency and free cash flow generation offers encouragement for future shareholder returns.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.